BX vs CME Stock Comparison
Compare BX and CME across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between BX and CME?
CME leads the current stock comparison as CME Group Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Blackstone Inc. vs CME Group Inc.
CME leads
CME leads by 10 AIQ points, primarily on Momentum and Risk Resilience, having only recently taken the lead back from BX.
Fragile: 3 of 6 evidence groups support CME, and the lead recently changed hands.
Blackstone Inc.
CME Group Inc.
The Algovestiq AIQ Score currently favors CME over BX, 52 versus 42 as of Sep 11, 2026. CME's advantage is driven primarily by stronger momentum and risk resilience. CME also shows the stronger technical structure relative to its 50-day moving average. 3 of 6 covered evidence groups favor CME today, and the comparison is rated Fragile on stability: only 3 of 6 covered evidence groups agree. CME lead: Reversed — BX led by 4 AIQ points 30 sessions ago; CME now leads by 10.
Compare Blackstone Inc. and CME Group Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare BX and CME against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum17 vs 54CME +37
- Risk Resilience44 vs 56CME +12
- Quality77 vs 74Even
- Value26 vs 26Even
3 of 6 evidence groups favor CME. CME’s edge is concentrated in momentum and risk resilience.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -1
No new signals fired.
Largest factor move: Momentum -5
No new signals fired.
CME's lead narrowed by 1 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — BX and CME both carry a full feed there.
The central trade-off
CME (CME Group Inc.): the stronger current systematic profile, led by momentum and risk resilience.
BX (Blackstone Inc.): the counter-case, on fundamentals — but at materially higher volatility, 32.2% against 21.7%.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
CMECME on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BXBX on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
CMECME on the Momentum factor, by 37 points.
Lower downside
CMECME on Risk Resilience, by 12 points.
Analyst upside
EvenAnalyst targets are level or not covered for both names.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BX | CME | Note |
|---|---|---|---|
| Implied upside to target | +14.2% | +14.9% | Level |
| Target dispersion | +44.3% | +32.2% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 9 | 6 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor CME. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | CME | 42 vs 52 |
| Fundamentals | BXon balance | revenue growth 16.3% vs -9.2%; EPS growth 89.2% vs -12%; TTM ROE 40.9% vs 15.5%; gross margin 88.8% vs 81.9%; operating margin 52.1% vs 65.1% — BX takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 26 vs 26 |
| Technicals | CME | Price vs 50-day -3.7% vs 5.3%; vs 200-day -4% vs -1.7% |
| Risk Resilience | CME | Risk Resilience 44 vs 56 |
| Analyst expectations | Even | Target upside 14.2% vs 14.9% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BX and CME and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is moderate at 10 points.
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has already changed hands inside the comparison window. (argues the conclusion is provisional)
- Signal direction runs against the verdict: the leader is net-bearish while the laggard is net-bullish. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on CME.
How the comparison changed
119 daily snapshots · May 4 – Sep 10CME lead: Reversed — BX led by 4 AIQ points 30 sessions ago; CME now leads by 10.
- Today
- CME +10
- 42 vs 52
- 7 sessions ago
- CME +7
- 50 vs 57
- 30 sessions ago
- BX +4
- 57 vs 53
- 90 sessions ago
- BX +5
- 50 vs 45
The lead changed hands 7 times in this window, most recently on Aug 14 when CME moved ahead of BX.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (2.07%)
- BB Lower Band Breach — bullish, volatility, short horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
0 bullish / 2 bearish
- Death Cross Active — bearish, trend, long horizon (6.50%)
- MACD Bearish Crossover — bearish, momentum, short horizon
BX is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +2.47%, AIQ 0 points).
Price is up while the AIQ Score moved down 1 points over the same session — price and model disagree (price +0.54%, AIQ -1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BX closes the Momentum gap — currently 37 points behind, the largest single contributor to CME's edge.
- 2BX's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
- 3CME starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
BX leads on balance| Metric | BX | CME |
|---|---|---|
| Revenue growth (YoY) | 16.3% | -9.2% |
| EPS growth (YoY) | 89.2% | -12% |
| Gross margin | 88.8% | 81.9% |
| Operating margin | 52.1% | 65.1% |
| Return on equity (TTM) | 40.9% | 15.5% |
| Debt to equity | 1.56 | 0.13 |
Performance
CME leads 4 of 6 windows| Metric | BX | CME |
|---|---|---|
| 1 week (5 sessions) | -8.3% | -1.3% |
| 1 month (20 sessions) | -14.3% | 4.5% |
| 3 months (63 sessions) | 5.8% | 3.9% |
| 6 months (126 sessions) | 16.9% | -9.6% |
| Year to date | -18.6% | 0.4% |
| 1 year (252 sessions) | -27.6% | 4.4% |
Technicals
CME has the stronger structure| Metric | BX | CME |
|---|---|---|
| RSI (14) | 18.3 | 53.9 |
| ADX (14) | 20.1 | 22.7 |
| Price vs 50-day | -3.7% | 5.3% |
| Price vs 200-day | -4% | -1.7% |
| Volatility (1M, annualized) | 32.2% | 21.7% |
Risk
CME is the more resilient| Metric | BX | CME |
|---|---|---|
| Beta | 1.35 | -0.32 |
| Sharpe ratio | -0.81 | 0.15 |
| Sortino ratio | -1.21 | 0.21 |
| Max drawdown | -45.9% | -33% |
| Current drawdown | -33.5% | -16.1% |
| Annualized volatility | 36.7% | 23.9% |
| Value at risk (95%) | -4.1% | -2.8% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BX or CME?
On the Algovestiq AIQ Score, CME is the stronger of the two as of Sep 11, 2026, scoring 52 against BX's 42. The edge comes from momentum and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BX or CME the better buy right now?
CME carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: only 3 of 6 covered evidence groups agree. Treat the lead as provisional.
Why does the AIQ Score favor CME over BX?
The composite weights Quality, Value, Momentum and Risk Resilience. CME leads Momentum by 37 points; CME leads Risk Resilience by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BX or CME?
Analyst price targets imply +14.2% upside for BX and +14.9% for CME. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BX or CME?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BX or CME?
BX on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BX or CME?
CME on the Momentum factor, by 37 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BX or CME?
CME is the more resilient of the two, so the other name carries the higher downside risk. CME on Risk Resilience, by 12 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BX more profitable than CME?
The profitability evidence is mixed: gross margin 88.8% vs 81.9%; operating margin 52.1% vs 65.1%; ttm roe 40.9% vs 15.5%. BX leads on two measures and CME on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is CME's lead over BX getting stronger or weaker?
CME lead: Reversed — BX led by 4 AIQ points 30 sessions ago; CME now leads by 10. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 7 times in that window, most recently on 2026-08-14, when CME moved ahead of BX.
What would change the BX vs CME verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BX closes the Momentum gap — currently 37 points behind, the largest single contributor to CME's edge; BX's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; CME starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about BX and CME?
BX: 3 bullish / 2 bearish, conflicted. CME: 0 bullish / 2 bearish. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BX is Golden Cross Active (bullish, long horizon). On CME it is Death Cross Active (bearish, long horizon).
Compare BX and CME with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.